SAM
SPRY icon

Smartleaf Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Smartleaf Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.3K Hold
1,952
– – ﹤0.01% 2101
2025
Q4 		$22.7K Buy
1,952
+1,400
+254% +$13.6K ﹤0.01% 1959
2025
Q3 		$5.37K Buy
+552
New +$7.92K ﹤0.01% 2355

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Smartleaf Asset Management's SPRY Position: Q1 2026 in Review

Smartleaf Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 1,952 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Smartleaf Asset Management first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. The position peaked at $22.7K in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Smartleaf Asset Management held 1,952 shares of ARS Pharmaceuticals worth $15.3K as of Q1 2026.
  • Smartleaf Asset Management left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2101 holding.
  • Smartleaf Asset Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's ARS Pharmaceuticals position peaked at $22.7K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.